Possible reasons and solutions for ineffectiveness of taking Osimertinib (Tagressa)

Osimertinib (Osimertinib) is a third-generation oral EGFR-TKI, mainly used for EGFR Mutation-positive non-small cell lung cancer (NSCLC) patients, including drug-resistant patients with T790M mutation. It achieves anti-tumor effects by selectively inhibiting EGFR mutant kinase activity and blocking tumor cell proliferation and survival. However, some patients experience unsatisfactory efficacy or disease progression after taking the drug, which may be related to a variety of factors.

One of the common reasons for the ineffectiveness of osimertinib is tumor resistance. As treatment time increases, tumors may develop C797S mutations or other EGFR non-targeted pathway activations (such as METamplification, HER2amplification), resulting in the inability of osimertinib to effectively inhibit the EGFR signaling pathway. In addition, tumor heterogeneity may make some cells less sensitive to drugs, resulting in reduced overall efficacy.

Differences in drug absorption and metabolism may also affect efficacy. For example, patients with impaired liver function or concurrent use of drugs that affect CYP3A4 metabolism may result in insufficient blood drug concentration, thereby reducing efficacy. In addition, irregular medication or missed doses may lead to unstable drug concentrations, preventing tumors from being effectively suppressed.

In the case where osimertinib is ineffective, the following measures can be taken: ① Re-conduct genetic testing to confirm whether the C797S mutation or other resistance mechanisms have occurred; ② Evaluate blood drug concentration and drug phase Interactions, ensure that patients take medications regularly as directed, and adjust dosage or change dosage regimens when necessary; ③ Consider combination or alternative treatments, such as combined use with MET inhibitors, chemotherapy or immunotherapy; ④ Closely monitor disease progression and adjust treatment strategies in a timely manner. Under the guidance of specialist physicians, individualized plans for different drug resistance mechanisms can improve treatment effects.

Reference materials:https://www.drugs.com/